Chronic Granulomatous Disease (CGD) Management Market Snapshot (2023 to 2033)

The global chronic Granulomatous disease (CGD) management market is expected to garner a market value of US$ 1.31 Billion in 2023 and is expected to accumulate a market value of US$ 2.11 Billion by registering a CAGR of 4.9% in the forecast period 2023 to 2033. Growth of the chronic Granulomatous disease (CGD) management market can be attributed to increasing research and development activities by key players for developing medications. the market for chronic Granulomatous disease (CGD) management registered a CAGR of 3.3% in the historical period 2018 to 2022.

The chronic granulomatous disease is a severe genetic condition that is passed down through the generations. People who suffer from this disease have weakened immune systems, making them subject to chronic inflammation and bacterial and fungal infections. The signs and symptoms of this condition appear in infancy or early childhood.

Report Attribute Details
Expected Market Value (2023) US$ 1.31 Billion
Anticipated Forecast Value (2033) US$ 2.11 Billion
Projected Growth Rate (2023 to 2033) 4.9% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Chronic Granulomatous Disease (CGD) Management Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Chronic Granulomatous disease (CGD) management reflected a value of 3.3% during the historical period, 2018 to 2022.

Chronic granulomatous disease or CGD is a kind of disorder under which white blood cells (phagocytes) are unable to kill certain types of bacteria and fungi. It is basically an inherited primary immunodeficiency disease caused by defects in the NADPH oxidase complex resulting in respiratory bursts in phagocytic leukocytes. The patients might develop skin infections, lymph node infections, pneumonia, lung infections, liver infections, gastrointestinal inflammation, or other infections. Thus, with the unique nature of CGD, the development of medications has increased rapidly. In the upcoming years, technological integration and research will boost the market for CGD management market.

Thus, the market for Chronic Granulomatous disease (CGD) management is expected to register a CAGR of 4.9% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Chronic Granulomatous Disease (CGD) Management Market?

Research and development activities boosting the growth of the CGD market

The fact that 1 in 200000 or 250000 people suffer from CGD makes it a rare disease. In addition, the signs and symptoms of this illness differ from person to person. Frequent bacterial and fungal infections, swollen lymph nodes, recurrent diarrhoea, and abscesses involving the liver, lungs, spleen, bones, or skin are some of the most prevalent signs and symptoms.

The market is expected to rise due to factors such as the rising prevalence of rare illnesses, increased healthcare spending in developed economies, and increased research and development activities.

Changing lifestyles along with advancements in technology to innovate medication accelerating market growth

Factors such as the changes adopted in lifestyle and alterations in food habits is further expected to accelerate the overall growth of the chronic granulomatous disease treatment market within the forecast period. Additionally, the growing prevalence of rare diseases in some developing countries and increasing research and development activities boost the overall market’s demand.

Additionally, the advancement in technology and rising government funding for the healthcare sector are to further extend suitable opportunities for the growth of the chronic granulomatous disease treatment market in the near future.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Chronic Granulomatous Disease (CGD) Management Market?

Expensive nature of the treatment along with the lack of awareness hampering the market growth

The unavailability of effective treatments for different types of chronic granulomatous disease along with the high cost associated with treatment and diagnostic tests of chronic granulomatous disease is anticipated to most likely obstruct the growth of the chronic granulomatous disease treatment market in the coming years.

The lack of awareness about the disease in developing and underdeveloped economies can be one of the challenging factors within the forecast period. For example, Genetic testing might cost anything from $100 to $2,000. All these factors are hampering the growth of the CGD market.

Region-Wise Insights

Rising Prevalence of CGD Boosting Market Growth in North America?

Research and development activities create lucrative opportunities for market growth

The North American region is expected to hold the largest market share for the CGD market. This is due to a well-developed healthcare sector, the rising prevalence of rare diseases, the steadily growing occurrence of chronic granulomatous disease (CGD), and a relatively large number of research and development activities in the North American region.

According to a 2017 report published by the National Center for Biotechnology Information (NCBI), CGD affects 1 in 200,000 to 1 in 250,000 births in the United States. This, in turn, has created lucrative opportunities for innovating medication for treating the ailment. Furthermore, increased government support for the healthcare sector in the region is another factor driving the growth of the market. Thus, the North American region is expected to dominate the Chronic Granulomatous Disease by possessing a 45% market share in 2023.

Expenditure on Research Activities Bolstering CGD Market Growth in Europe?

Development of the healthcare sector shaping the landscape for the CGD market

The rising prevalence of rare diseases, as well as increased research and development activities, are driving market growth in this region. According to Eurostat, gross domestic expenditure (GERD) on research and development was EUR 303 billion in 2016.

In addition, increasing government funding for the healthcare sector and increasing research and development activities are changing the landscape for the CGD market. With the strong presence of key players in the region, Europe is expected to hold a 35% market share in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Presence of X-linked CGD in Males Bolstering Segment Growth?

Detection of symptoms in early age advancing growth of X-linked CGD

Based on the Type, the market is segmented into X-Linked Chronic Granulomatous Disease and Autosomal Recessive Chronic Granulomatous Disease.

Patients with X-linked CGD often develop infections in their first ten years of life, and around 40% of them die before they reach the age of 35. Males are more likely than females to develop the chronic granulomatous disease. Approximately two-thirds of people in North American and European research had the X-linked recessive type of the disease. CGD is present at birth because it is a hereditary condition.

CGD symptoms normally appear throughout childhood or early adolescence, but they can sometimes be delayed until the early adolescent years. The earliest symptoms have been found to appear in adults in a few cases. The chronic granulomatous disease affects approximately four to five people in every Billion people globally.

Thus, the X-Linked Chronic Granulomatous Disease segment is expected to possess 52% market for the CGD market in 2023.

Effectiveness of Antibiotic Medication Increasing Dependency on Trimethoprim?

Trimethoprim exhibiting promising results for treating CBD

Based on the Treatment, the market is segmented into Infection Management, Trimethoprim, Sulfamethoxazole, Itraconazole, Interferon-gamma, Stem cell transplantation, and others. Trimethoprim is expected to hold the largest share of the CGD market in 2023.

Continuous antibiotic medication to help prevent infections, such as trimethoprim for bacterial infections and itraconazole for fungal infections, is used to treat chronic granulomatous illness. Antibiotics are usually required for infections. Corticosteroid medications can also help with granulomatous consequences. In some people with CGD, bone marrow transplants have been shown to be beneficial.

Thus, Trimethoprim is expected to possess a 40% market share for the CGD market in 2023.

Market Key Players Promoting Products and Services in Hospitals Due to Its Increasing Convenience?

Hospitals increasing accessibility for treatment of CBD management market

Based on the end-user, the market is segmented into Hospitals, Clinical laboratories, and Others. The hospital segment is expected to hold the largest market share in 2023.

This is due to the growing number of Chronic Granulomatous Disease patients increasing the treatments of Chronic Granulomatous Disease in hospitals. Hospitals are a significant part of the healthcare industry and a key source of revenue for the overall industry, which stimulates research and innovation.

As a result, a number of firms devote large resources to promoting their products and services among hospitals, both in terms of revenue and marketing tactics. Due to these factors, strategic decisions made in the hospital sector can have an impact on other sectors of the healthcare industry, providing them significant control over contract conditions with suppliers, service providers, and distributors.

These are the key factors that are expected to drive the growth of the hospital segment in the Chronic Granulomatous Disease Market during the forecast period. Thus, hospitals are expected to possess a 40% market share in the CBD management market.

Market Competition

Key players in the chronic Granulomatous disease (CGD) management market are Clinigen Group plc, Orchard Therapeutics plc, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc, Merck KGaA

  • Pfizer Inc, a key player in the CGD management market is investing in extensive research for innovating medications to reduce the efficiency of the symptoms caused by CGD.
  • Novartis AG, another key player in the CGD management market is focusing on integrating technology and commercializing medication for CGD management.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 1.31 Billion
Market Value in 2033 US$ 2.11 Billion
Growth Rate CAGR of 4.9% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Type
  • Diagnosis
  • Treatment
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)
Key Countries Profiled
  • The United States of America
  • Canada
  • Brazil
  • Argentina
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • Association of Southeast Asian Nations (ASEAN)
  • GCC
  • South Africa
Key Companies Profiled
  • Clinigen Group plc
  • Orchard Therapeutics plc2032
  • Horizon Therapeutics plc
  • ViroMed. Co. Ltd
  • Bellicum Pharmaceuticals, Inc
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • Novartis AG
  • Lonza
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc
  • Merck KGaA
Customization Available Upon Request

Key Segments Profiled in the Chronic Granulomatous Disease (CGD) Management Industry Survey

Type:

  • X-Linked Chronic Granulomatous Disease
  • Autosomal Recessive Chronic Granulomatous Disease

Diagnosis:

  • Neutrophil Function Tests
  • Genetic Testing
  • Prenatal Testing

Treatment:

  • Infection Management
  • Trimethoprim
  • Sulfamethoxazole
  • Itraconazole
  • Interferon-gamma
  • Stem Cell Transplantation
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

Frequently Asked Questions

What is the market size in 2023?

The industry will reach a market value of US$ 1.31 billion in 2023.

What was the projected growth rate from 2018 to 2022?

The market witnessed 3.3% historically.

What is North America's expected share in 2023?

North America is likely to generate 45% revenue in 2023.

How market for Europe is projected to grow in 2023?

Europe's market size is expected to hold a 35% share in 2023.

What is the CAGR from 2023 to 2033?

The market is expected to record a 4.9% CAGR until 2033.

Table of Content

1. Executive Summary | Chronic Granulomatous Disease (CGD) Management Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033

        5.3.1. X-Linked Chronic Granulomatous Disease

        5.3.2. Autosomal Recessive Chronic Granulomatous Disease

    5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033

        6.3.1. Neutrophil Function Tests

        6.3.2. Genetic Testing

        6.3.3. Prenatal Testing

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        7.3.1. Infection Management

        7.3.2. Trimethoprim

        7.3.3. Sulfamethoxazole

        7.3.4. Itraconazole

        7.3.5. Interferon-gamma

        7.3.6. Stem Cell Transplantation

        7.3.7. Others

    7.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033

        8.3.1. Hospitals

        8.3.2. Clinical Laboratory

        8.3.3. Homecare

        8.3.4. Others

    8.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033

9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. South Asia

        9.3.5. East Asia

        9.3.6. Oceania

        9.3.7. Middle East & Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. USA

            10.2.1.2. Canada

        10.2.2. By Type

        10.2.3. By Diagnosis

        10.2.4. By Treatment

        10.2.5. By End-User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Diagnosis

        10.3.4. By Treatment

        10.3.5. By End-User

    10.4. Key Takeaways

11. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Type

        11.2.3. By Diagnosis

        11.2.4. By Treatment

        11.2.5. By End-User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Diagnosis

        11.3.4. By Treatment

        11.3.5. By End-User

    11.4. Key Takeaways

12. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. US

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Type

        12.2.3. By Diagnosis

        12.2.4. By Treatment

        12.2.5. By End-User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Diagnosis

        12.3.4. By Treatment

        12.3.5. By End-User

    12.4. Key Takeaways

13. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Rest of South Asia

        13.2.2. By Type

        13.2.3. By Diagnosis

        13.2.4. By Treatment

        13.2.5. By End-User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Diagnosis

        13.3.4. By Treatment

        13.3.5. By End-User

    13.4. Key Takeaways

14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Type

        14.2.3. By Diagnosis

        14.2.4. By Treatment

        14.2.5. By End-User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Type

        14.3.3. By Diagnosis

        14.3.4. By Treatment

        14.3.5. By End-User

    14.4. Key Takeaways

15. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. Australia

            15.2.1.2. New Zealand

        15.2.2. By Type

        15.2.3. By Diagnosis

        15.2.4. By Treatment

        15.2.5. By End-User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Type

        15.3.3. By Diagnosis

        15.3.4. By Treatment

        15.3.5. By End-User

    15.4. Key Takeaways

16. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Type

        16.2.3. By Diagnosis

        16.2.4. By Treatment

        16.2.5. By End-User

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Type

        16.3.3. By Diagnosis

        16.3.4. By Treatment

        16.3.5. By End-User

    16.4. Key Takeaways

17. Key Countries Analysis

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Type

            17.1.2.2. By Diagnosis

            17.1.2.3. By Treatment

            17.1.2.4. By End-User

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Type

            17.2.2.2. By Diagnosis

            17.2.2.3. By Treatment

            17.2.2.4. By End-User

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Type

            17.3.2.2. By Diagnosis

            17.3.2.3. By Treatment

            17.3.2.4. By End-User

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Type

            17.4.2.2. By Diagnosis

            17.4.2.3. By Treatment

            17.4.2.4. By End-User

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Type

            17.5.2.2. By Diagnosis

            17.5.2.3. By Treatment

            17.5.2.4. By End-User

    17.6. UK

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Type

            17.6.2.2. By Diagnosis

            17.6.2.3. By Treatment

            17.6.2.4. By End-User

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Type

            17.7.2.2. By Diagnosis

            17.7.2.3. By Treatment

            17.7.2.4. By End-User

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Type

            17.8.2.2. By Diagnosis

            17.8.2.3. By Treatment

            17.8.2.4. By End-User

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Type

            17.9.2.2. By Diagnosis

            17.9.2.3. By Treatment

            17.9.2.4. By End-User

    17.10. India

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Type

            17.10.2.2. By Diagnosis

            17.10.2.3. By Treatment

            17.10.2.4. By End-User

    17.11. Malaysia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Type

            17.11.2.2. By Diagnosis

            17.11.2.3. By Treatment

            17.11.2.4. By End-User

    17.12. Singapore

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Type

            17.12.2.2. By Diagnosis

            17.12.2.3. By Treatment

            17.12.2.4. By End-User

    17.13. Thailand

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Type

            17.13.2.2. By Diagnosis

            17.13.2.3. By Treatment

            17.13.2.4. By End-User

    17.14. China

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Type

            17.14.2.2. By Diagnosis

            17.14.2.3. By Treatment

            17.14.2.4. By End-User

    17.15. Japan

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Type

            17.15.2.2. By Diagnosis

            17.15.2.3. By Treatment

            17.15.2.4. By End-User

    17.16. South Korea

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Type

            17.16.2.2. By Diagnosis

            17.16.2.3. By Treatment

            17.16.2.4. By End-User

    17.17. Australia

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Type

            17.17.2.2. By Diagnosis

            17.17.2.3. By Treatment

            17.17.2.4. By End-User

    17.18. New Zealand

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Type

            17.18.2.2. By Diagnosis

            17.18.2.3. By Treatment

            17.18.2.4. By End-User

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Type

            17.19.2.2. By Diagnosis

            17.19.2.3. By Treatment

            17.19.2.4. By End-User

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Type

            17.20.2.2. By Diagnosis

            17.20.2.3. By Treatment

            17.20.2.4. By End-User

    17.21. Israel

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Type

            17.21.2.2. By Diagnosis

            17.21.2.3. By Treatment

            17.21.2.4. By End-User

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Type

        18.3.3. By Diagnosis

        18.3.4. By Treatment

        18.3.5. By End-User

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Clinigen Group plc

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Orchard Therapeutics plc2032

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Horizon Therapeutics plc

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. ViroMed. Co. Ltd

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Bellicum Pharmaceuticals, Inc.

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Pfizer Inc.

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. F. Hoffmann-La Roche Ltd

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Novartis AG

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Lonza

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. GlaxoSmithKline plc.

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

        19.1.11. Eli Lilly and Company

            19.1.11.1. Overview

            19.1.11.2. Product Portfolio

            19.1.11.3. Profitability by Market Segments

            19.1.11.4. Sales Footprint

            19.1.11.5. Strategy Overview

                19.1.11.5.1. Marketing Strategy

        19.1.12. Johnson & Johnson Services, Inc.

            19.1.12.1. Overview

            19.1.12.2. Product Portfolio

            19.1.12.3. Profitability by Market Segments

            19.1.12.4. Sales Footprint

            19.1.12.5. Strategy Overview

                19.1.12.5.1. Marketing Strategy

        19.1.13. Merck KGaA

            19.1.13.1. Overview

            19.1.13.2. Product Portfolio

            19.1.13.3. Profitability by Market Segments

            19.1.13.4. Sales Footprint

            19.1.13.5. Strategy Overview

                19.1.13.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Infectious Disease Diagnostics Market

June 2024

REP-GB-1208

250 pages

Healthcare

Autoimmune Disease Therapeutics Market

July 2023

REP-GB-1238

324 pages

Healthcare

Rheumatic-Heart Disease Management Market

January 2023

REP-GB-16349

289 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Chronic Granulomatous Disease (CGD) Management Market

Schedule a Call